SOURCE Q BioMed Inc
Mannin assigned world class industry mentors and advisors
NEW YORK, March 17, 2016 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to congratulate Mannin Research on its selection to the C2MP program and the exceptional mentors and advisors now included in the long list of industry experts available to assist in advancing these important technologies.
The C2MP program is a tailor-made mentoring program focused on life science innovators. In partnership with the Chicago Innovation Mentors (CIM@MATTER) organization, the Canadian Trade Commissioner Service will catalyze and accelerate technology commercialization opportunities in the Chicago area by matching experienced and supportive mentoring teams with early stage innovators. Mannin Research was selected to take part in the program so as to accelerate the development and commercialization of Mannin’s lead indication, MAN-01 for Primary Open-Angle Glaucoma. CIM@MATTER was established in 2010 based on the VMS program at the Massachusetts Institute of Technology.
CIM@MATTER has seven member institutions, and nearly 200 mentors as part of its innovation network. The C2MP program has provided Mannin with a mentor and a group of advisors from a team of life science and business professionals within the CIM@MATTER team and dedicated support from the Trade Commissioner Service of Canada.
Mannin’s lead mentor, David Kempner, has more than 20 years of experience consulting on the business aspects of biotechnology preceded by eight years of experience in a broad spectrum of biological and biochemical research projects. David is the founder and Managing Director of Integrated Market and Technology Assessments Inc., a management consulting firm providing technical market research and corporate/business development services to pharmaceutical, diagnostic and biotechnology companies in the U.S. He was also the co-founder and Executive VP Corporate development of NovaDx, a venture diagnostic firm founded to identify novel diagnostic markers and develop through proof of concept.
Michael Rosen is Managing Director of Rosen Biosciences Strategies, a life science economic development consultancy focusing on enabling international life science companies to enter the U.S. market. Prior to this, he was Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises. He has spent 20 years in senior management positions with Pfizer, Bristol-Myers Squibb and Searle/Monsanto, and spent 12 years as President/CEO of European and U.S. biotech and medical device companies in the areas of cancer, neuroscience, woundcare and kidney disease. Mr. Rosen is a founder, former Vice-Chairman and current board member of the Illinois Biotechnology Industry Organization.
Gayle Kirkpatrick is an accomplished business development executive with 20+ years of experience in Fortune 100 healthcare corporations and major academic research institutions. She has led due diligence for numerous pipeline and company acquisitions, and has expertise in technology transfer, licensing, acquisitions, strategic alliances, and venture investment. She has held senior positions at Astellas and AbbVie/Abbott and has served on several boards including chair of the BioForward board (the Wisconsin state affiliate organization of BIO).
Catherine Sazdanoff is a global healthcare executive with experience in leadership roles across corporate development, business development, operations, legal and risk management. She has a JD from Northwestern University and has held senior positions at Abbot Laboratories, and Takeda Pharmaceuticals. Catherine is also a member of the board of Meridian Bioscience Inc. and an advisor to mProve Health, LLC.
Kris Rothleutner, is an experienced pharmaceutical industry professional and successful entrepreneur. He is currently the Director of Life Cycle Management (Orphan Business Unit) at Horizon Pharma, and has held senior positions at Takeda Pharmaceuticals, and has also worked with Abbot Laboratories.
Mannin’s CEO, Dr. George N. Nikopoulos stated. “We are thrilled to be apart of the program. We see the value in the acceleration process as it relates to our development and commercialization milestones. We thank the Canadian Trade Commissioner Service in Chicago for their support and look forward to a successful program.”
In October 2015 Q BioMed Inc entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics. Mannin’s primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and children, using a research platform designed to help develop new drugs for that indication and cystic kidney disease, among other diseases. Lead drug candidate MAN-01 is designed to treat abnormal vessels within the eye-thus treating glaucoma at its root causes.
We invite our shareholders and interested parties to subscribe to our email list and stay informed on our website at http://www.qbiomed.com and follow us on the social media feeds we use.
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need?.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
©2016 PR Newswire. All Rights Reserved.
